BioRestorative Therapies (BRTX) Cash & Current Investments (2010 - 2025)

BioRestorative Therapies (BRTX) has 15 years of Cash & Current Investments data on file, last reported at $3.0 million in Q4 2025.

• Quarterly Cash & Current Investments fell 72.49% year-over-year to $3.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.0 million (down 72.49% YoY) and the FY2025 annual result came in at $3.0 million, down 72.49% from the prior year.
• Cash & Current Investments slipped to $3.0 million in Q4 2025, from $4.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $30.5 million in Q1 2024 to a low of $1.1 million in Q3 2021.
• A 5-year average of $12.2 million and a median of $12.4 million in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2021 — Cash & Current Investments soared 52220.27% — and 2025, when it slumped 72.49%.
• Tracing BRTX's Cash & Current Investments over 5 years: stood at $21.0 million in 2021, then declined by 29.85% to $14.7 million in 2022, then retreated by 24.97% to $11.1 million in 2023, then dropped by 3.01% to $10.7 million in 2024, then tumbled by 72.49% to $3.0 million in 2025.
• The last three Cash & Current Investments figures came in at $3.0 million (Q4 2025), $4.5 million (Q3 2025), and $7.4 million (Q2 2025), per Business Quant data.